Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 45, Issue 4, pp 486–495 | Cite as

Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study

  • Siavash Piran
  • Caroline Gabriel
  • Sam Schulman
Article

Abstract

Direct oral factor Xa (FXa) inhibitors are widely used for anticoagulation but a targeted antidote is not available. Four-factor prothrombin complex concentrate (4FPCC) has been shown in observational studies to support hemostasis in most patients with major bleeding related to FXa inhibitors with an acceptable rate of thromboembolic events. However, the effectiveness of 4FPCC for reversal of FXa inhibitors prior to emergency surgery or invasive procedures is unclear. A retrospective chart review was performed in patients that received 4FPCC at Hamilton General Hospital from 2015 to 2017. The primary effectiveness outcome was based on the comment of the surgeon on the adequacy of the hemostasis. If no such comment was documented, the case was discussed with a surgeon specialized in the type of surgery/procedure performed to obtain their best opinion. The principal safety outcome was thromboembolic events including venous thromboembolism, ischemic stroke, systemic embolism or myocardial infarction during 7 days after surgery. A total of 247 patients that had received 4FPCC were initially screened and 21 were on a FXa inhibitor and had emergency surgery/procedure. The mean age was 74 ± 11 years, and 14 (66.7%) were males. Hemostasis was rated as good in most patients (18 of 21, 85.7%). There were no thromboembolic events. The all-cause mortality rate was 28.6%; 2/3 of these patients had an intracranial hemorrhage. Hemostasis was rated as good in most patients with no thromboembolic events observed. Prospective studies assessing the safety and effectiveness of 4FPCC for this indication are needed.

Keywords

Direct factor Xa inhibitors Emergency surgery Reversal Prothrombin complex concentrate 

Notes

Funding

SP was a recipient of a CanVECTOR thrombosis fellowship.

Compliance with ethical standards

Conflict of interest

Dr. Schulman has received a research grant from Octapharma for a previous study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 383:955–962Google Scholar
  2. 2.
    Kakkos SK, Kirkilesis GI, Tsolakis IA (2014) Editor’s Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 48(5):565–575CrossRefPubMedGoogle Scholar
  3. 3.
    Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI (2017) Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med 377(5):431–441CrossRefPubMedGoogle Scholar
  4. 4.
    Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M (2016) ANNEXA-4 investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217CrossRefPubMedGoogle Scholar
  6. 6.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579CrossRefPubMedGoogle Scholar
  7. 7.
    Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH (2014) Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 12(9):1428–1436CrossRefPubMedGoogle Scholar
  8. 8.
    Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131(1):82–90CrossRefPubMedGoogle Scholar
  9. 9.
    Grandhi R, Newman WC, Zhang X, Harrison G, Moran C, Okonkwo DO, Ducruet AF (2015) Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg 84(6):1956–1961CrossRefPubMedGoogle Scholar
  10. 10.
    Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J, Hempel EL, Magnusson M, Frisk T, Schulman S (2017) Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 130(15):1706–1712CrossRefPubMedGoogle Scholar
  11. 11.
    Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, Carrier M, Crowther MA, Ghosh I, Lazo-Langner A, Zondag M (2018) Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Accepted in Thromb HaemostGoogle Scholar
  12. 12.
    Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24(1):6–46CrossRefPubMedGoogle Scholar
  13. 13.
    Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol 70(24):3042–3067CrossRefPubMedGoogle Scholar
  14. 14.
    Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H (2008) Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 6(4):622–631CrossRefPubMedGoogle Scholar
  15. 15.
    Altorjay Á, Szabó É, Boda Z, Kramer L, Ngo LY, Engl W, Firth CL, Ahlstrom ER, Gelmont DM, Pabinger I (2015) An international, multicenter, prospective study of a prothrombin complex, Prothromplex Total complex®, in anticoagulant reversal. Thromb Res 135(3):485–491CrossRefPubMedGoogle Scholar
  16. 16.
    Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S (2010) Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 41(12):2860–2866CrossRefPubMedGoogle Scholar
  17. 17.
    Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F (2013) Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75(2):476–487CrossRefPubMedGoogle Scholar
  18. 18.
    Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873–880CrossRefPubMedGoogle Scholar
  19. 19.
    Kubitza D, Becka M, Roth A, Mueck W (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24(10):2757–2765CrossRefPubMedGoogle Scholar
  20. 20.
    Cuker A, Siegal D (2015) Monitoring and reversal of direct oral anticoagulants. Hematol Am Soc Hematol Educ Program 2015:117–124Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Siavash Piran
    • 1
  • Caroline Gabriel
    • 1
  • Sam Schulman
    • 1
    • 2
  1. 1.Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research InstituteMcMaster UniversityHamiltonCanada
  2. 2.Thrombosis ServiceHHS - General HospitalHamiltonCanada

Personalised recommendations